Vimarsana
Biggest News Aggregation in the World

Marcel Nally News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marcel Nally. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marcel Nally Today - Breaking & Trending Today

EXECUTIVE CHANGES: Psych Capital names new CEO; Shuka appoints chair -November 07, 2023 at 02:30 pm EST - Vimarsana News

EXECUTIVE CHANGES: Psych Capital names new CEO; Shuka appoints chair -November 07, 2023 at 02:30 pm EST

The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News: ---------- Canadian Overseas Petroleum Ltd -...

CyanConnode PLC jumps after alliance with Californian group - Vimarsana News

CyanConnode PLC jumps after alliance with Californian group

Oxford Biomedica shares surge after it raises its forecast for COVID-19 vaccine revenues A look at the major movers on the London market on Tuesday Oxford Biomedica PLC (LON:OXB) has been boosted by vaccine news. The company, a key manufacturer of the Oxford/AstraZeneca PLC (LON:AZN) COVID-19 vaccine, has doubled its expectations for revenue from the contract. The gene and cell therapy group said AstraZeneca had increased the number of batches required for the jab in the second half. It now estimates its revenues from the vaccine will be £100mln, up from previous forecasts of £50mln. T...

Oxford Biomedica PLC shares surge after it raises its forecast for COVID-19 vaccine revenues - Vimarsana News

Oxford Biomedica PLC shares surge after it raises its forecast for COVID-19 vaccine revenues

Oxford Biomedica shares surge after it raises its forecast for COVID-19 vaccine revenues A look at the major movers on the London market on Tuesday Oxford Biomedica PLC (LON:OXB) has been boosted by vaccine news. The company, a key manufacturer of the Oxford/AstraZeneca PLC (LON:AZN) COVID-19 vaccine, has doubled its expectations for revenue from the contract. The gene and cell therapy group said AstraZeneca had increased the number of batches required for the jab in the second half. It now estimates its revenues from the vaccine will be £100mln, up from previous forecasts of £50mln. T...